Boulevard Bio launches with $65 million from Deerfield and world-class founders
The company is focusing on B-cell-driven autoimmune diseases
Advertisement
Boulevard Bio announced its emergence from stealth with $65 million from founding investor Deerfield Management and early Phase 1 healthy volunteer data for lead candidate BLVD101, a dual BAFF/APRIL-targeting bispecific antibody, supporting a 12-week (quarterly) dosing interval in IgA nephropathy (IgAN). Founded by pioneers in B cell biology and incubated by Deerfield Management within Deerfield Discovery and Development (3DC), the firm’s internal therapeutics research and development engine, Boulevard’s approach is grounded in a deep understanding of B cell disease biology, the identification of key mechanisms and targets that drive pathology, and the ability to engineer multi-specific antibodies to address those drivers. The company aims to optimize each of the three candidates in its pipeline to improve the quality of life a chronic illness often erodes.
“Today, over five million patients with B cell-driven autoimmune disease face a lifetime of treatments that may relieve symptoms temporarily but fail to address the underlying cause,” said Mahesh Karande, chief executive officer of Boulevard. “Leveraging a deep understanding of B cell biology, Boulevard aims to free patients from a lifetime of burdensome treatment, offering durable disease control and, in some cases, the prospect of a cure. Each program in our pipeline was designed and selected for that goal, and the early data from our lead program are a promising indication that the science behind them has the potential to deliver what patients expect and deserve. We are fortunate to work alongside experienced leaders in immunology and rheumatology as we build Boulevard Bio.”
Prof. Georg Schett, MD, co-founder of Boulevard, added, “Over the past two decades, B cells have become recognized as central drivers of autoimmune disease, but addressing their complex biology likely requires the design of precision medicines that can be combined to target specific, sometimes-overlapping mechanisms and indications. We founded Boulevard to meet that challenge, with multi-target strategies and a thoughtful selection of modalities to appropriately reach key disease drivers and alter the course of chronic illnesses.”
Frank Nestle, MD, Boulevard scientific co-founder, board member, and partner at Deerfield Management, and chief executive officer of 3DC, added, “Today we are excited to publicly welcome Boulevard Bio into the world – a company incubated at Deerfield with molecules developed inside 3DC, now led by a seasoned team with experience translating complex science into best- and first-in-class medicines. Since the company’s inception, the Boulevard team has advanced BLVD101 to early clinical data that highlight this compound’s potential to achieve durable disease control in a large, underserved patient population. I have great confidence in Boulevard’s pipeline and the team driving it forward as they aim to advance differentiated and impactful treatments for patients burdened with lifelong autoimmune diseases.”
Leadership & Financing
Boulevard Bio is led by Mahesh Karande, Chief Executive Officer, and Neil Solomons, MD, Chief Medical Officer. The company’s board is chaired by Brian Chow, PhD, Managing Director at Deerfield Management; Deerfield Partner and 3DC CEO Frank Nestle, MD, is scientific co-founder and serves on the board. Boulevard was co-founded by Prof. Georg Schett, MD, a pioneer in immune reset, alongside founding advisor Prof. Jonathan Barratt, PhD, FRCP. Boulevard has raised approximately $65 million in aggregate financing from Deerfield and affiliates in equity capital and convertible notes.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous